Both changes in ratio of CD8+/CD4+ T cells and FVS indicated that ccRCC-01, 03, 06 were responsive, while ccRCC-02 and 04 were resistant to toripalimab (Fig. 3C). The gene discussed is CD4; the disease is nonpapillary renal cell carcinoma.